23 recruiting, 17 not yet recruiting, 11 active not recruiting, 11 completed. 71 Phase 2, 19 Phase 1.
Follow polatuzumab vedotin: new trials by email Literature Review of polatuzumab vedotin trials Research Report on polatuzumab vedotin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial Polatuzumab Vedotin, Acalabrutinib, Mosunetuzumab - Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | University of Washington | 27 | 2027-03-01 | 2026-11-02 |
| TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma Tafasitamab, Polatuzumab vedotin, Glofitamab - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | Brown University | 30 | 2026-11-01 | 2026-09-01 |
| Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Nodal Marginal Zone Lymphoma | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 138 | 2026-10-03 | 2026-10-13 |
| A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP Polatuzumab vedotin, Glofitamab - Diffuse Large B-cell Lymphoma | Phase 2 | Not yet recruiting | Yonsei University | 47 | 2026-09-01 | 2026-07-14 |
| Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas Glofitamab, Epcoritamab, Polatuzumab Vedotin - Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Relapsed or Refractory B-cell Lymphoma | Phase 2 | Recruiting | National Research Center for Hematology, Russia | 40 | 2026-09-01 | 2026-10-20 |
| The CARDIOPROTECT Trial Dexrazoxane, Dexrazoxane placebo, Doxorubicin - Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 60 | 2026-08-31 | 2026-07-27 |
| AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL Polatuzumab Vedotin, Rituximab (R), Zanubrutinib - Large B-Cell Lymphoma (LBCL) | Phase 2 | Not yet recruiting | Ruijin Hospital | 112 | 2026-06-30 | 2026-07-21 |
| Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma R-CHOP+Orelabrutinib, POLA-R-CHP+orelabrutinib, R-miniCHOP +orelabrutinib - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Ou Bai, MD/PHD | 66 | 2026-06-16 | 2026-07-01 |
| Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL Polatuzumab Vedotin, Rituximab, Cyclophosphamide - Large B-cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 40 | 2026-06-15 | 2026-06-30 |
| Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma Polatuzumab Vedotin, Mosunetuzumab, Cyclophosphamide - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Medical College of Wisconsin | 31 | 2026-06-01 | 2026-08-25 |
| AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL Polatuzumab Vedotin, rituximab, Cyclophosphamide - Large B-Cell Lymphoma (LBCL) | Phase 2 | Not yet recruiting | Ruijin Hospital | 178 | 2026-05-06 | 2026-05-19 |
| Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL Polatuzumab Vedotin, Rituximab (R), Chidamide - Double Expressor DLBCL | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 68 | 2026-04-01 | 2026-02-17 |
| The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL Pola-ZR-Glo (Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Glofitamab) regimen - Large B-Cell Lymphoma (LBCL) | Phase 2 | Recruiting | Ruijin Hospital | 30 | 2026-03-31 | 2026-05-08 |
| CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL Chidamide, Rituximab, Polatuzumab Vedotin - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 58 | 2026-02-03 | 2026-07-29 |
| Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma Glofitamab; Polatuzumab vedotin; Zuberitamab; Cyclophosphamide; Doxorubicin; Prednisone - DLBCL - Diffuse Large B Cell Lymphoma, Chemo-free Therapy | Phase 2 | Not yet recruiting | Li Zhiming | 40 | 2026-01-15 | 2025-11-19 |
| G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy - Aggressive B-Cell Lymphoma | Phase 2 | Not yet recruiting | Navy General Hospital, Beijing | 80 | 2025-10-01 | 2025-09-22 |
| G-Pola-ZLP in Diffuse Large B-Cell Lymphoma Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy - Diffuse Large B-Cell Lymphoma | Phase 2 | Not yet recruiting | Navy General Hospital, Beijing | 80 | 2025-09-24 | 2025-08-14 |
| Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pirtobrutinib, R-GemOx, Polatuzumab Vedotin - Relapsed and Refractory DLBCL | Phase 2 | Not yet recruiting | Ruijin Hospital | 22 | 2025-08-05 | 2025-08-14 |
| Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL Glofitamab, Polatuzumab Vedotin, Zanubrutinib - Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Shanghai Zhongshan Hospital | 38 | 2025-06-20 | 2026-10-16 |
| A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 Polatuzumab Vedotin, Rituximab, Cyclophosphamide - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 134 | 2025-06-20 | 2025-06-24 |
Showing 20 of 71. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (35) · Lymphoma, B-Cell (10) · Lymphoma, Non-Hodgkin (8) · Recurrence (8) · Lymphoma (7) · Lymphoma, Follicular (7) · Lymphoma, Mantle-Cell (5) · Lymphoma, B-Cell, Marginal Zone (4) · Dendritic Cell Sarcoma, Interdigitating (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Hodgkin Disease (2) · Burkitt Lymphoma (1) · Cardiotoxicity (1) · Hematologic Neoplasms (1) · Leukemia, Hairy Cell (1)
Hoffmann-La Roche (8) · Ruijin Hospital (7) · University of Washington (4) · Navy General Hospital, Beijing (3) · City of Hope Medical Center (2) · Genentech, Inc. (2) · Peng Liu (2) · SWOG Cancer Research Network (2) · Washington University School of Medicine (2) · Academic and Community Cancer Research United (1) · Affiliated Hospital of Nantong University (1) · Barbara Ann Karmanos Cancer Institute (1) · Beth Israel Deaconess Medical Center (1) · Brown University (1) · Celgene (1)
United States (38) · China (20) · Spain (9) · France (7) · Germany (7) · United Kingdom (7) · Italy (6) · Austria (5) · Belgium (5) · Poland (5) · South Korea (5) · Czechia (4) · Israel (4) · Netherlands (4) · Australia (3)
Liren Qian, PhD (2) · Adam Olszewski (1) · Alex F Herrera (1) · Barbara Kiesewetter, MD (1) · Boyu Hu (1) · Brad Haverkos (1) · Brian T Hess (1) · Catherine S Diefenbach (1) · Christine Ryan, MD (1) · Christopher Dittus, DO, MPH (1) · David A Russler-Germain, M.D., Ph.D. (1) · Dipenkumar Modi, M.D. (1)
PMID 32770353, PMID 39319495, PMID 32705923, PMID 30935953, PMID 31101489, PMID 31693429, PMID 33028076, PMID 34749395, PMID 34826412, PMID 35086141, PMID 35182224, PMID 36521030, PMID 37581593, PMID 37981564, PMID 38072960, PMID 38190832, PMID 38843483, PMID 39908481, PMID 40532125, PMID 40802906, PMID 41115257, PMID 41845899, PMID 41894687, PMID 42013019, PMID 42283231, PMID 42600120, PMID 42832423, PMID 42837325
2015 (3), 2018 (2), P30CA033572 (2), U10CA180888 (2), 2014 (1), 2023 (1), P30CA015083 (1), P30CA022453 (1), P30CA046934 (1)